Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC_EX:A61K39/395

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/182197LIQUID COMPOSITION COMPRISING ANTIBODY OF HUMAN INTERLEUKIN-4 RECEPTOR ALPHA
WO 17.09.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/CN2020/079120 Applicant SUZHOU CONNECT BIOPHARMACEUTICALS, LTD. Inventor ZHENG, Wei
The present invention provides a liquid composition comprising an antibody of human interleukin-4 receptor alpha. The liquid composition comprises the antibody at a concentration of 50-200 mg/ml; and a buffer, a protectant, and a surfactant as adjuvants. The liquid composition has a pH of 5.4-6.4.
2.WO/2020/183147IMMUNOTHERAPY COMBINED WITH AN ANTI-CD38 ANTIBODY
WO 17.09.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/GB2020/050567 Applicant AUTOLUS LIMITED Inventor PEDDAREDDIGARI, Vijay
The present invention relates to the use of an anti-CD38 antibody in a subject undergoing immunotherapy wherein the anti-CD38 antibody is administered before and/or after immunotherapy.
3.WO/2020/185677BIO-RESPONSIVE ANTIBODY COMPLEXES FOR ENHANCED IMMUNOTHERAPY
WO 17.09.2020
Int.Class A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Appl.No PCT/US2020/021709 Applicant NORTH CAROLINA STATE UNIVERSITY Inventor GU, Zhen
Disclosed are bioresponsive protein complexes comprising immune checkpoint blockade inhibitors and methods of their use.
4.WO/2020/181376TSG-6 ANTIBODIES AND USES THEREFOR
WO 17.09.2020
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Appl.No PCT/CA2020/050321 Applicant UNIVERSITY HEALTH NETWORK Inventor BROKX, Richard
The invention provides novel anti-TSG-6 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
5.WO/2020/181846CYSTEINE-CONTAINING ANTIBODY, DRUG CONJUGATE AND USE THEREOF
WO 17.09.2020
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2019/123219 Applicant XDCEXPLORER (SHANGHAI) CO., LTD. Inventor XIE, Zhenhui
Provided are a cysteine-containing antibody, a drug conjugate and a use thereof. The heavy chain constant region of the antibody is a humanized γ1 chain, and the light chain constant region thereof is a humanized κ chain, wherein amino acid residues at an A site of the heavy chain constant region and/or at a B site of the light chain constant region are replaced with cysteine, so as to provide an active site for site-directed coupling with drugs.
6.WO/2020/183245ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES
WO 17.09.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/IB2020/000342 Applicant JANSSEN PHARMACEUTICA NV Inventor GANESAN, Rajkumar
Anti-Vβ17/anti-CD123 bispecific antibodies or antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies.
7.WO/2020/185635ADAM17 BINDING MOLECULES AND USES THEREOF
WO 17.09.2020
Int.Class A01K 67/027
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
67Rearing or breeding animals, not otherwise provided for; New breeds of animals
027New breeds of vertebrates
Appl.No PCT/US2020/021603 Applicant MEMORIAL SLOAN KETTERING CANCER CENTER Inventor WHITE, Thomas, Edgeworth
The present invention provides various ADAM17 binding molecules (including antibodies and fragments thereof), compositions comprising such ADAM17 binding molecules, and methods of using such ADAM17 binding molecules and compositions, for example in inhibiting binding of ADAM17 to ADAM17 substrates (such as ErbB ligands), in inhibiting the proliferation of cancer cells, and in treating cancer.
8.WO/2020/185805IMMUNE MODULATION BY BREQUINAR
WO 17.09.2020
Int.Class A61K 31/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
Appl.No PCT/US2020/021939 Applicant CLEAR CREEK BIO, INC. Inventor SYKES, David, Brian
The invention provides technologies for the improvement of immuno-oncology therapy. The present disclosure encompasses the recognition that brequinar may be useful in improving the safety and efficacy of immuno-oncology (IO) treatments. The goal of IO is to use patient's own immune system to eliminate cancerous cells. Examples of IO treatments may include hematopoietic stem cell transplantation (HSCT), cancer vaccines (alone or in combination with adoptive T cell immunotherapy), monoclonal antibodies (mAbs), and chimeric antigen receptor (CAR) T cell therapy.
9.WO/2020/186204PRAME BINDING MOLECULES AND USES THEREOF
WO 17.09.2020
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2020/022729 Applicant ULMERT, Hans, David, Staffan Inventor ULMERT, Hans, David, Staffan
The present invention provides various PRAME binding molecules (including antibodies, antibody fragments, chimeric antigen receptors, and the like), compositions and cells (including T cells) comprising such PRAME binding molecules, and methods of using such PRAME binding molecules, compositions and cells, for example in the detection and/or monitoring of PRAME-positive tumors.
10.WO/2020/185533GROWTH DIFFERENTIATION FACTOR 15 COMBINATION THERAPY
WO 17.09.2020
Int.Class A61K 38/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
18Growth factors; Growth regulators
Appl.No PCT/US2020/021314 Applicant AMGEN INC. Inventor XIONG, YuMei
The present disclosure provides combination therapy with GDF15 molecules. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region, optionally via a linker. In one embodiment, combination therapy comprises administration of a GDF15 molecule with a GLP-1R agonist. In another embodiment, combination therapy comprises administration of a GDF15 molecule with a GIPR antagonist.